Cost-effectiveness of implantable cardioverter-defibrillators in Brazil: Primary prevention analysis in the public sector

Value in Health

Volumn 13, Issue 2, 2010, Pages 160-168

  Ribeiro, Rodrigo Antonini ^a   Stella, Steffan Frosi ^a,b   Camey, Suzi Alves ^a   Zimerman, Leandro Ioschpe ^a,b   Pimentel, Maurício ^b   Rohde, Luis Eduardo ^a,b   Polanczyk, Carísi Anne ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Chronic heart failure; Cost effectiveness; Implantable cardioverter defibrillators; Primary prevention

Indexed keywords

ADULT; AGED; ARTICLE; BRAZIL; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; FEMALE; HEALTH CARE SYSTEM; HEART ARRHYTHMIA; HEART FAILURE; HIGH RISK PATIENT; HUMAN; MALE; MONEY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROBABILITY; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; SIMULATION; SURVIVAL TIME;

EID: 77149131809     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00608.x     Document Type: Article

References (55)

1. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998 19 (Suppl. P P9 16.
2. Hoes AW, Mosterd A, Grobbee DE. An epidemic of heart failure? Recent evidence from Europe. Eur Heart J 1998 19 (Suppl. L L2 9.
3. Krum H, Stewart S. Chronic heart failure: time to recognize this major public health problem. Med J Aust 2006 184 : 147 148.
4. Stewart S, MacIntyre K, Capewell S, McMurray JJ. Heart failure and the aging population: an increasing burden in the 21st century? Heart 2003 89 : 49 53.
5. Ministério da Saúde/SVS. Sistema de Informaçõ es de Mortalidade (SIM). 2004. Available from: http://tabnet.datasus.gov.br/CGI/ idb2006/matriz.htm [Accessed August 16, 2009].
6. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996 335 : 1933 1940.
7. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997 337 : 1569 1575.
8. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999 341 : 1882 1890.
9. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002 105 : 1453 1458.
10. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 346 : 877 883.
11. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J Am Coll Cardiol 2003 41 : 1707 1712.
12. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004 350 : 2140 2150.
13. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004 350 : 2151 2158.
14. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004 351 : 2481 2488.
15. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 352 : 225 237.
16. Nanthakumar K, Epstein AE, Kay GN, et al. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004 44 : 2166 2172.
17. Special report: cost-effectiveness of implantable cardioverter defibrillators in a MADIT-II population. Technol Eval Cent Asses Program Exec Summ 2004 19 : 1 2.
18. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2006 114 : 135 142.
19. Mushlin AI, Hall WJ, Zwanziger J, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation 1998 97 : 2129 2135.
20. Neyt M, Thiry N, Ramaekers D, Van Brabandt H. Cost effectiveness of implantable cardioverter-defibrillators for primary prevention in a Belgian context. Appl Health Econ Health Policy 2008 6 : 67 80.
21. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005 353 : 1471 1480.
22. Boriani G, Biffi M, Martignani C, et al. Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs. Eur J Heart Fail 2003 5 : 419 425.
23. Sanders G, Hlatky M, Owens D. Cost-effectiveness of implantable cardioverter-defibrillators in a MADIT-II population. TEC Assess 2004 19 : 1 26.
24. Al-Khatib SM, Anstrom KJ, Eisenstein EL, et al. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med 2005 142 : 593 600.
25. Zwanziger J, Hall WJ, Dick AW, et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006 47 : 2310 2318.
26. Banz K. Cardiac resynchronization therapy (CRT) in heart failure - a model to assess the economic value of this new medical technology. Value Health 2005 8 : 128 139.
27. Rohde LE, Beck-da-Silva L, Goldraich L, et al. Reliability and prognostic value of traditional signs and symptoms in outpatients with congestive heart failure. Can J Cardiol 2004 20 : 697 702.
28. Rohde LE, Clausell N, Ribeiro JP, et al. Health outcomes in decompensated congestive heart failure: a comparison of tertiary hospitals in Brazil and United States. Int J Cardiol 2005 102 : 71 7.
29. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996 276 : 1253 1258.
30. Al-Khatib SM, Sanders GD, Mark DB, et al. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J 2005 149 : 1020 1034.
31. Ezekowitz JA, Rowe BH, Dryden DM, et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med 2007 147 : 251 262.
32. Alter P, Waldhans S, Plachta E, et al. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol 2005 28 : 926 932.
33. Schoels W, Swerdlow CD, Jung W, et al. Worldwide clinical experience with a new dual-chamber implantable cardioverter defibrillator system. J Cardiovasc Electrophysiol 2001 12 : 521 528.
34. Bardy GH, Yee R, Jung W. Multicenter experience with a pectoral unipolar implantable cardioverter-defibrillator. Active Can Investigators. J Am Coll Cardiol 1996 28 : 400 410.
35. Takahashi T, Bhandari AK, Watanuki M, et al. High incidence of device-related and lead-related complications in the dual-chamber implantable cardioverter defibrillator compared with the single-chamber version. Circ J 2002 66 : 746 750.
36. Rosenqvist M, Beyer T, Block M, et al. Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. European 7219 Jewel ICD investigators. Circulation 1998 98 : 663 670.
37. Kleemann T, Becker T, Doenges K, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation 2007 115 : 2474 2480.
38. Luria D, Glikson M, Brady PA, et al. Predictors and mode of detection of transvenous lead malfunction in implantable defibrillators. Am J Cardiol 2001 87 : 901 904.
39. Cook J, Glick H, Kinosian B, Heyse J. Ladder of Life" score as a value measure for health status in congestive heart failure. Med Decis Making 1993 13 : 386.
40. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993 13 : 89 102.
41. Sanders GD, Hlatky MA, Every NR, et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med 2001 135 : 870 883.
42. Costa R, da Silva KR, Mendonca RC, et al. Incidence of shock and quality of life in young patients with implantable cardioverter-defibrillator. Arq Bras Cardiol 2007 88 : 258 264.
43. Chen RH, Chen KP, Wang FZ, et al. Incidence and causes of inappropriate detection and therapy by implantable defibrillators of cardioversion in patients with ventricular tachyarrhythmia. Chin Med J (Engl) 2006 119 : 557 563.
44. McDonald K, Hornberger J, Ziegler J, Lenert L. Health-related quality of life for patients at risk of sudden cardiac death: amiodarone versus implantable cardioverter defibrillators. Med Decis Making 2000 20 : 501.
45. Mark DB, Anstrom KJ, Sun JL, et al. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med 2008 359 : 999 1008.
46. Passman R, Subacius H, Ruo B, et al. Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study. Arch Intern Med 2007 167 : 2226 2232.
47. Araujo DV, Tavares LR, Verissimo R, et al. Cost of heart failure in the Unified Health System Arq Bras Cardiol 2005 84 : 422 427.
48. World Bank. World Development Indicators. 2008. Available from: http://siteresources.worldbank.org/DATASTATISTICS/Resources/WDI08-section1- intro.pdf [Accessed August 16, 2009].
49. Instituto Brasileiro de Geografia e Estatística. PIB cresce 3,7% e chega a R$ 2,3 trilhões em 2006. Available from: http://www1.ibge.gov.br/home/presidencia/noticias/noticia-visualiza.php? id-noticia=850&id-pagina=1 [Accessed August 16, 2009 H, Thiry N, Neyt M, et al. The Implantable Cardioverter Defibrillator: A Health Technology Assessment. Health Technology Assessment (HTA). Brussels : Belgian Health Care Knowledge Centre (KCE), 2007.
50. Rohde LE, Palombini DV, Polanczyk CA, et al. A hemodynamically oriented echocardiography-based strategy in the treatment of congestive heart failure. J Card Fail 2007 13 : 618 625.
51. Rassi A Jr. Implantable ardioverter-defibrillators in patients with Chagas heart disease: misperceptions, many questions and the urgent need for a randomized clinical trial. J Cardiovasc Electrophysiol 2007 18 : 1241 1243.
52. da Fonseca SM, Belo LG, Carvalho H, et al. Clinical follow-up of patients with implantable cardioverter-defibrillator. Arq Bras Cardiol 2007 88 : 8 16.
53. Toscano CM, Duncan BB, Mengue SS, et al. Initial impact and cost of a nationwide population screening campaign for diabetes in Brazil: a follow up study. BMC Health Serv Res 2008 8 : 189.
54. Polanczyk CA, Wainstein MV, Ribeiro JP. Cost-effectiveness of sirolimus-eluting stents in percutaneous coronary interventions in Brazil. Arq Bras Cardiol 2007 88 : 464 474.
55. Chen L, Hay JW. Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther 2004 18 : 161 170.